Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. - Wikidata - awgldk - TriplyDB

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.

http://www.wikidata.org/entity/Q35780315

about

Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies Clinical significance of tumor-infiltrating lymphocytes in breast cancer 4-1BB agonism: adding the accelerator to cancer immunotherapy Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates Mechanisms of action of therapeutic antibodies for cancer Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop.Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients Targeting CD137 enhances the efficacy of cetuximab.Targeting secondary immune responses to cetuximab: CD137 and the outside story.Oncogene withdrawal engages the immune system to induce sustained cancer regression.An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.New Immunotherapy Strategies in Breast Cancer.Combination immunotherapy: a road map.Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.Classification of current anticancer immunotherapies Agonist antibodies to TNFR molecules that costimulate T and NK cells NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma.NK cell-based immunotherapies in Pediatric Oncology.Present and Future of Allogeneic Natural Killer Cell Therapy Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells Introduction to monoclonal antibodies.Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism.Adaptive Immune Responses and HER2/neu Positive Breast Cancer.Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.Targeting breast cancer stem cells with HER2-specific antibodies and natural killer cells.Emerging therapeutic targets in metastatic progression: A focus on breast cancer.Noncanonical roles of the immune system in eliciting oncogene addiction Identification of CD245 as myosin 18A, a receptor for surfactant A: A novel pathway for activating human NK lymphocytes The immune system and inflammation in breast cancer.CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation.

P2860

Q24605057-50D38929-1624-4BA9-8790-79835EAEACA1 Q26822730-1A2BB040-747C-42FC-A736-FDA7DB947AB9 Q27012963-F2C16E03-F0AA-441D-8239-7F82264EC2A6 Q27694769-714A09A2-D18C-4238-9C2A-AD636348E5E2 Q28070214-15284449-B9E3-4E74-8FFC-CEF1DCFBB63F Q28079622-ED86E6FD-0505-4E7A-92D7-3E4AD8059C75 Q28083123-D344C561-8074-4F08-B6D8-4EC13EA8E3FC Q28385366-88B5B2BE-ED3A-4C44-854D-BF11A21B083A Q30456436-AC8B3C3D-4B42-459A-96E7-59EB432C328A Q33809528-065E661D-E2BE-43F0-A3E2-44342C794B3C Q33872482-EAC76F0B-C145-4ABA-81C6-B31DC148CCC8 Q33872496-1539D90C-A2E5-469E-9D2C-45A48E7675C9 Q33987633-7DC00FD7-FE5F-4611-97E9-8BAC8CCB8AD8 Q34361976-4C549C40-7172-4155-BF7A-69858CA841BA Q34549227-49770032-D5BC-4200-BFC9-3C7EAD363026 Q34552128-19BEE1EF-9D99-4D00-A09B-94A03CFA2A82 Q34978570-BA3542AD-E86F-4115-BABD-C998E4DFFF89 Q35149637-C1292C04-45B0-48D8-A12B-4DB1B10448C5 Q35427446-D21CA119-862D-4812-B469-8372B818BB74 Q35506745-DAEF5F16-5931-4336-873A-32E1D76FE1A8 Q35600975-3E53790D-553A-48D3-841A-94CB46B2C1F4 Q35677351-C4EA45D1-B2BF-49DD-8081-C5A5F5B8BD99 Q35764479-44273A72-F69C-4F89-B450-B6467DF332B9 Q35918911-804489A3-724D-42B7-8EE8-249999FF14CC Q36050008-17E46074-47EF-4E4A-B5AF-F0981F8373B9 Q36440214-1E231C3C-A52D-44A3-9969-6D903F583B10 Q36449290-16CBB049-E46A-4FA1-B2FE-0592C24D0CA1 Q36522770-2DB07B3A-907E-4B54-BF7A-FC9502BC8E02 Q36535465-F7AF0977-E1DD-4451-8DA4-B17FF21F88E0 Q36539682-53E458DA-6893-4C11-A3BC-966853ADC87D Q36597479-9CD92895-F769-47BF-BA99-6609113B7A28 Q36607857-8990AC7E-C1E4-41F1-ABA3-04EF1AEFE8FF Q36729376-51CC2571-C190-43B9-868D-800967903807 Q36758890-925E9DDF-EE8E-4A37-8FB4-92793C2A47E6 Q36854062-D6449BF8-2FA4-4E06-8912-E677404FC070 Q36931816-68177FF1-DD50-49B8-8BFA-AE7991FD2DB1 Q37012676-DA0521AE-2315-4D0B-ADA0-D5EE40915AE5 Q37033451-1EAAE1D1-3674-49A0-9720-BE23AED22D3D Q37130209-D2D7853F-4F55-4BCE-90A7-260FA76E234A Q37155165-8F1696B2-ECEA-44B9-815E-BD9682AD2DD5

P2860

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.

http://www.wikidata.org/entity/Q35780315

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Stimulation of natural killer ...... plant models of breast cancer.

@ast

Stimulation of natural killer ...... plant models of breast cancer.

@en

type

label

Stimulation of natural killer ...... plant models of breast cancer.

@ast

Stimulation of natural killer ...... plant models of breast cancer.

@en

prefLabel

Stimulation of natural killer ...... plant models of breast cancer.

@ast

Stimulation of natural killer ...... plant models of breast cancer.

@en

P1433

Q35780315-9CB940D1-A29F-49F6-B272-4FD1DA5D1618

P1476

Q35780315-FA3D45D4-7744-4F6E-B4CB-9F81DDA82E1A

P2093

Q35780315-0521AC0D-1E8F-4959-BCC6-B9E2EC65620A

Q35780315-0871BB94-E431-48CE-951D-0CF59D5BD4A5

Q35780315-43AA964C-DA43-454B-978C-553ADFC9E147

Q35780315-4A37317D-4CBB-4D45-B363-A9D3CC982CBC

Q35780315-795CD3A6-4CC3-420A-A50B-67082E659612

Q35780315-92FE3EAD-43F8-4BB6-A635-9E2904765B2C

Q35780315-9886A182-C62D-4231-9D45-76DB31FED210

Q35780315-98C1D2CE-BE51-4DED-A415-6124163EB7AD

Q35780315-B614C6E7-6640-46E5-98FC-66482AE8D8A3

Q35780315-B8756E0F-5A75-43D0-866D-79475B0F1CD1

P2860

Q35780315-040522A7-AD45-421A-959B-2C4183B9B421

Q35780315-08B36D0E-D6A5-4AE8-B93F-70C17030D200

Q35780315-0D87E202-C456-4862-A9E5-2FE183DE1D92

Q35780315-1003A28C-7858-4A34-B116-0818DDAF62BD

Q35780315-1190B139-DCC0-41B6-811E-2ED77E4BAC71

Q35780315-1F9A13FD-612C-459C-ADC1-FEA7D3B49E78

Q35780315-212938EB-31A5-4602-A8A0-03B4D5E9B437

Q35780315-24E652FB-7D76-4B39-A1B2-A91414C5CD6D

Q35780315-25760556-8E7A-4143-A9E8-83070E4E163B

Q35780315-26C561CB-9A4E-4539-B2EC-DEF8F7B25646

P304

Q35780315-D8E28F60-002B-4CE1-A24A-A6F06EF2EE1E

P31

Q35780315-0468AED1-FC96-4E4F-8F7B-870106CE11A4

P356

Q35780315-7A5DF114-1537-4CBE-A577-05DF3ED53116

P407

Q35780315-75934854-C648-43E9-ACBB-26C9E50FA2C2

P433

Q35780315-D9EE64B4-79F5-404E-9749-7C2B9772ACA4

P478

Q35780315-0E03E835-1329-4E6C-85F8-67E3B3B961DD

P577

Q35780315-CFA150C0-C706-4A47-A6DC-5811F65A531E

P698

Q35780315-CF17F7F8-5801-4A71-A17F-30295852BF27

P921

Q35780315-46B482AB-1ED8-4842-8EAA-9FD7CD6A6CD8

Q35780315-7E86E85D-6F72-4A44-8096-6083CD42463F

P932

Q35780315-D9BA98C6-94F8-4809-8EE4-E2D911B71F78

P356

P1433

Journal of Clinical Investigation

P1476

Stimulation of natural killer ...... plant models of breast cancer.

@en

P2093

A Dimitrios Colevas

http://www.w3.org/2001/XMLSchema#string

Debra Czerwinski

http://www.w3.org/2001/XMLSchema#string

Ferenc Scheeren

http://www.w3.org/2001/XMLSchema#string

Frank E Stockdale

http://www.w3.org/2001/XMLSchema#string

Holbrook E Kohrt

http://www.w3.org/2001/XMLSchema#string

Joseph A Mollick

http://www.w3.org/2001/XMLSchema#string

Kipp Weiskopf

http://www.w3.org/2001/XMLSchema#string

Lieping Chen

http://www.w3.org/2001/XMLSchema#string

Matthew J Goldstein

http://www.w3.org/2001/XMLSchema#string

Michael F Clarke

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Cutting edge: Expression of functional CD137 receptor by dendritic cells

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells.

Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells.

4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines

A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.

A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.

Regulation of granulocyte and macrophage populations of murine bone marrow cells by G-CSF and CD137 protein

P304

1066-1075

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI61226

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22326955

http://www.w3.org/2001/XMLSchema#string

P921

P932

3287235

http://www.w3.org/2001/XMLSchema#string